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Background
Poor tumor accumulation of chemotherapeutics and diffusive transport limitations 
due to high intra-tumoral pressures (Jain 2001), altered architecture of tumoral-vas-
culature networks, and heterogeneous cell populations (Weiswald et  al. 2015) repre-
sents a major clinical challenge in the treatment of cancer (Chauhan et al. 2011; Kleeff 
et  al. 2007; Hicks et  al. 2003; Lankelma et  al. 1999; Minchinton and Tannock 2006; 
Primeau et al. 2005). Hyperthermia in combination with chemotherapy has been widely 
used in attempts to overcome these barriers or enhance the potency of the standard 
chemotherapy (van der Zee 2002; Owusu et  al. 2013); however, the clinical applica-
tion of hyperthermia for cancer treatment has been hampered by the inability to 
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deliver thermal doses to deep seated tumor tissues. Several methods and techniques 
have been historically proposed for clinical hyperthermia [e.g., (Cheung and Neyzari 
1984)], including whole-body and interstitial heating techniques as well as heating via 
externally placed electromagnetic and ultrasound power sources. We have recently 
found that high-intensity short-wave radiofrequency (RF) electric fields may reach 
regions inaccessible via conventional modes of generating tumor hyperthermia (Ware 
et  al. 2015) and specifically affect tumor vasculature and dense tumor micro-regions 
to enhance the delivery and extravasation of chemotherapeutics. This phenomenon is 
aided by the low tissue-specific absorption rates and widespread whole-body penetra-
tion of RF radiation. The altered dielectric properties and energy dissipation efficacy of 
malignant versus normal tissues means hyperthermia can be preferentially delivered to 
tumor sites (Raoof et al. 2013; Song 1984) whilst minimizing heating of adjacent healthy 
tissues. However, there is still a lack of knowledge of the time-resolved innate inter-
action between RF fields and tumor vasculature, drug molecules or nanoparticle (NP) 
vectors, and therefore, efficient treatment schedules have yet to be determined. These 
deficiencies are partly due to researchers often using ‘end point’ measures of total drug 
concentration and comparing results between tumors grown in different species. This 
practice leads to the loss of information regarding the time kinetics and process of drug 
delivery, and further compounding inter-tumor, or even intra-tumor heterogeneity, 
inevitably causes difficulties in results interpretation.
Real-time imaging via intravital microscopy (IVM) is a technique where time-resolved 
high-definition images may be observed in a particular tumor region, as the tumor 
undergoes a specific treatment schedule, and thus, details on process may be achieved, 
whilst negating issues of intra- and inter-tumoral heterogeneity. IVM has been employed 
to gain insight into the delivery, perfusion, biokinetics and biodistribution of fluores-
cent molecules, drugs and NPs (van de Ven et al. 2013). While there are various con-
figurations in IVM setup, the basic procedure involves the imaging of an organ or tumor 
under a confocal microscope in an anesthetized animal during the delivery of fluores-
cently-labeled molecules or NPs. Variations in IVM procedure and setup are thoroughly 
reviewed by van de Ven et al. (2013). As this procedure can yield a wealth of quantita-
tive and semi-quantitative data, its use is of potentially great value in the investigation 
of intra-tumoral biokinetics and biodistribution of drug and NPs under RF hyperther-
mia. However, the integration of IVM with high-powered RF electric fields is difficult to 
achieve, as the RF field has the capacity to interfere with the many electrical and non-
electrical components of the IVM system.
In combination therapy, RF hyperthermia has been demonstrated to enhance drug 
and NP efficacy, decreasing cancer cell proliferation in combination with chemo-
therapy (Zhang et  al. 2014) and decreasing tumor volume in combination with 
chemotherapy (Zhang et  al. 2014) or silicon NPs (Tamarov et  al. 2014) as well as 
increasing drug deposition dose (Zhang et al. 2014) and increase perfusion of fluo-
rescent tracers to tumor (Corr et al. 2015), transporting these materials deeper into 
cancerous tissues. Whilst studies have provided ex situ and end-point metrics dem-
onstrating the therapeutic effects of RF hyperthermia (Ware et al. 2015; Zhang et al. 
2014), these data lack the real-time information critical to understanding the in-
process physiological effects, pharmacokinetics and physicochemical mechanisms 
Page 4 of 19Lapin et al. Cancer Nano  (2016) 7:5 
involving both hyperthermic and non-hyperthermic phenomena at work in RF 
hyperthermia therapy before, during and after delivery of nanomedicines. With the 
real-time observation of NP biokinetics and physiological response provided by 
IVM, researchers and clinicians will gain a mechanistic perspective on RF hyper-
thermia-assisted NP delivery and hence a broader and more complete understanding 
of the effects of RF hyperthermia as a therapeutic, ultimately accelerating its transla-
tion to the clinic.
Our goal is to provide an accurate protocol that describes the safe integration of IVM 
imaging with a high-powered non-invasive RF field. The technique will allow detailed 
observation over time of the effects of the RF field on kinetics and biodistribution of 
NP delivery at the microvascular level in live 4T1 tumor-bearing mice. These observa-
tions will allow insight into the interaction between the RF field, the vasculature, and a 
model NP and will be a useful tool in determining the most efficient RF field treatment 
schedule for the enhancement of cancer drugs and NP carrier tumor localization.
Methods
The intersection of IVM observation with RF hyperthermia treatment will likely be a 
subset of the feasible applications of each. Investigators should be advised that testing 
may be necessary to determine whether in  situ imaging is possible under the desired 
treatment modality and setup limitations. Figure 1 shows a schematic of the overall RF-
IVM procedure with data analysis methods.
All experiments were performed with the approval of the Institutional Animal Care 
and Use Committee of the Baylor College of Medicine and established protocols 
followed.
Fig. 1 Schematic summarizing all relevant procedures including animal preparation and IVM imaging during 
RF field exposure, followed by data processing and analysis
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Experimental design and controls
Due to heterogeneity within the tumor microenvironment both within different regions 
of the same tumor (intra-tumoral) and across different tumors within one or more ani-
mals (inter-tumoral), it is recommended to maintain the same microenvironment struc-
tures (e.g., microvasculature, tissue, and cells) within the microscope field of view for the 
duration of the experiment.
To achieve this, the IVM video of a specific region of the tumor microenvironment can 
be recorded continuously before, during, and after NP intravenous injection, followed 
by RF field exposure, where the video of the same region continues during and after the 
RF field is turned off. Limitations on the ability to maintain self-consistent imaging are 
addressed in the discussion section. With this methodology, changes in the biodistri-
bution of different drugs and NPs can be self-referenced to earlier time points, includ-
ing post-to-pre-RF field exposure. Furthermore, continuous video provides insight into 
kinetics beyond what is possible with end-point analysis alone.
To compare biodistribution and kinetics between tumor and normal tissue, in this 
study, we took advantage of the presence of microvasculature with normal features 
adjacent to that with tumor-like features within the same IVM video. Various types and 
stages of tumor vasculature in murine mammary carcinoma at the microenvironment 
level have previously been characterized morphologically and compared to normal vas-
culature by the visual inspection of IVM images (Boucher et  al. 1996). In addition to 
the comparison of normal and tumor-like vasculature adjacent at the microenvironment 
level, the entire procedure with continuous video can be repeated in a separate region of 
normal tissue within the same animal and of the same organ or tissue type as that of the 
tumor.
Materials
Excitation and emission spectra of tracer and NPs should be well characterized and care 
should be taken to separate the emission spectra for each reagent. In the current study, 
Alexafluor-647 Bovine Serum Albumin (BSA; 10 mg/mL in PBS, Thermo Fisher Scien-
tific) was used as a vascular flow tracer, and water soluble carboxylic acid functionalized 
cadmium selenide/zinc sulfide core/shell nanocrystal quantum dots (QDs; NN Labs, 
USA) with a diameter of 10 nm and a zeta potential of −20 mV were used as a model NP 
to demonstrate NP perfusion into the tumor microenvironment. QD absorption/emis-
sion spectra are presented in Additional file 1: Figure S1.
RF‑IVM setup
Figure 2 shows the RF-IVM setup prior to positioning of the anesthetized mouse. Panel 
A shows the main components of the setup: the RF amplifier (1) level with the micro-
scope stage and positioned just lateral to the objective lens of the confocal microscope 
(2). Easily connectable anesthesia tubing (3) is located behind the microscope stage. The 
position of the mouse stage (arrow) located directly under the objective and to the left of 
the RF amplifier is controlled by an XYZ servo-controller (4). The RF amplifier (hereto-
fore referred to as the portable RF device) should be connected to a computer to control 
RF output power and to a power supply cooled by a chiller (not shown).
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The portable RF device is positioned (shown in Fig.  2, Panel B), such that it is cen-
tered vertically with the objective lens and centered horizontally between the tip of the 
objective lens and the mouse stage. The cross-hair center of the RF transmission antenna 
Fig. 2 Panel a RF setup including RF amplifier (1), confocal microscope objective lens (2), anesthesia tubing 
(3) coming from behind the microscope stage and XYZ servo‑controller (4) for the mouse stage (indicated by 
the red arrow) above the microscope stage. Panel b Positioning of the RF transmission antenna (TX) against 
the side of the objective lens with TX center point directly below the lens. Lines on the mouse stage indicate 
optimal positioning of tumor Y‑direction location. Panel c. The receiving antenna (RX) is directly opposite the 
TX, with centers lined up. Yellow arrows indicate the grounding wire connecting copper tape on the mouse 
stage to the RX, which is itself grounded. The red arrow points to a glass coverslip that locates the tumor in 
the Z‑direction, optionally located by an XYZ positioner
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(TX in Panel C) will be adjusted to the exact position of the mouse tumor during the 
procedure. The receiving antenna (RX in Panel C) is positioned against the mouse stage 
directly opposite and in line with the TX. Yellow arrows in Panel C show the grounding 
wire connecting the copper bed of the mouse stage to a grounding wire connected to 
the RX. The red arrow in Panel C points to a glass coverslip that will locate the tumor 
in the z-direction. Note that connecting arm to the coverslip, positioned by a manual 
XYZ positioner here is optional and must be non-heating and non-interacting with the 
RF field. Alternatively, the coverslip can be placed on the surface of the exposed mouse 
tumor. Be aware that all XYZ components that extend into the RF field (the volumetric 
space connecting the squares of the transmission and receiving antennas) must be pre-
tested to characterize their RF heating profiles and potential to spark at a range of RF 
power wattages prior to running the experiment. Be certain to test to a power higher 
than that planned for use. Ungrounded metal must never be exposed to the RF field.
Water-immersion objective lens (16X used here) should be selected for magnification 
beyond 10X. Position RF transmission and receiving heads (TX and RX RF antennas) on 
either side of the microscope, so that centers line up. Precision adjustments are made 
during the procedure to select the field of view.
Animal characterization and preparation
Female Balb/c mice are housed in the standard temperature and lighting conditions with 
free access to food and water. Acclimated mice were injected with the 4T1 cells (105 
cells/50 μL) into the left inguinal mammary fad pad as previously described by Pulaski 
and Ostrand-Rosenberg (2001). Because of the mammary gland development, care was 
taken to develop the tumor (3–5 mm average diameter) in 9–12 week old mice.
Animals were anesthetized by isoflurane inhalation in oxygen (the anesthesia level was 
maintaining by adjustment of the isoflurane concentration, 0.8–2.2 %). Each mouse was 
kept on a warming pad and/or under a heating lamp to maintain body temperature dur-
ing and after imaging. Mouse body temperature was monitored by fiber optic probe.
Procedure
Preparation of mice for tail vein injection and skin flap non‑survival surgery
The first step requires mouse anesthetization in a chamber with 2 % isofluorane. Next, 
the animal should be transferred to the customized heated stage (~40  °C) fitted with 
a nosecone connected to the anesthesia line and the mouse’s nose secured to the line 
with tape. The stage is customized to fit under a microscope objective lens and between 
the TX and RX antennas of a custom-built portable RF device. In additional, the stage 
must be covered with a sheet of copper tape in position, where the mouse will lie. When 
working with animals with fur, e.g., Balb/c mice, be certain to remove all hair from the 
animal’s abdomen. After mouse placement, the mouse tail vein should be cannulated 
(Haney et al. 2009). This is a two-phase procedure; the first stage requires the insertion 
of the standard 24G i.v. catheter before being flushed with 0.2–0.3 mL of 1 % Heparin 
solution in saline. Afterward, stretched PE 10 Intramedic Polyethylene Tubing (Becton–
Dickinson) should be inserted into the cannula. Finally, the double catheter is secured 
by tape and glue (VetBond®). Note that heparin flush must be repeated periodically and 
immediately after other i.v. injections to prevent clotting which may occlude the vessel.
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The preparation for skin-flap surgery requires bringing the mouse to a deep plane of 
anesthesia (surgery plane). This can be achieved by maintaining the mouse at 2 % iso-
fluorane for a sufficient amount of time (time for tail cannulation should suffice) and 
ensuring that there is no pain response. Next, the extremities of the mouse are fixed to 
the heated stage by applying copper tape to all four limbs and part of the tail close to 
the field avoiding the cannulated region of the tail. If desired, certain limbs can be taped 
together with copper tape (including at the nosecone) as appropriate without hindering 
the setup. Care should be taken to express the mouse bladder to avoid additional fluid 
in the RF field (bladder cannulation should be considered for long-term imaging proto-
cols). At this point, the performance of skin-flap surgery may be carried out. This step 
requires: (1) creation of a midline incision; (2) gentle but firm usage of a cotton swab 
soaked with PBS to separate the fascia from the dermis; (3) suturing of skin flap in two 
or three locations (stretch sutures across the platform and over a small non-metallic, 
non-heating pad to support the tumor in the skin flap); (4) mounting the sutures to the 
side of the XYZ-controlled platform using surgical tape.
Setup of mouse in IVM system with retro‑fitting of portable RF device
After mouse preparation, transfer the heated stage affixed with the mouse to the position 
under the objective lens of the confocal microscope, securing it to the holder connected 
to the XYZ-servo-controlled platform. Move the TX RF antenna within 2–3 mm of the 
side of the confocal microscope objective lens. Next, place a coverslip over the tumor, 
thoroughly wetting both the sides with PBS and bringing part of the tumor into focus. 
Next, switch to computer control of the microscope and select laser percent power and 
detection gain settings for excitation and emission.
Figure  3 shows the anesthetized mouse with open skin flap on the XYZ-servo-con-
trolled platform in the RF-IVM setup. Copper tape is used both to ground the mouse 
to the platform and secure its nose to the isofluorane, Panel A. As shown in Panel B, 
the water-immersion lens is positioned over the coverslip, and coverslip over the 
tumor such that PBS creates a continuous optical path with these items. In Panel C, RX 
and TX antennas are brought as close to the platform as possible to maximize signal 
transmission.
Imaging procedure with in situ RF field exposure for tumor
After localization of fluorescence signal of tracer in tumor vessels, the position of infra-
red (IR) camera (FLIR SC 6000, FLIR Systems, Inc., Boston, MA) should be optimized, 
so tumor and normal tissue have temperature readings. Care should be taken to obtain 
IR photos every 30  s or run continuous IR video during the whole experimental time 
(prior, during, and post-RF). Afterward, the continuous IVM video can be started. The 
tracer-loaded syringe is attached to the cannula, and fluorescently-labeled tracer is 
slowly injected at ~5 μl/s. Next, the i.v. line is flushed with Heparin solution to remove 
reagents from the tubing. The NP solution loaded syringe is connected to the cannula, 
and injection is performed. Flushing with Heparin solution is then repeated. After the 
initiation of RF at 10 W, gradually reach 50–75 W over 5 min. When RF irradiation is 
complete, continue running video for 10–30 min or longer.
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Image analysis
Movies were collected from the IVM system and were input into ImageJ software 1.49U 
(National Institutes of Health, USA). For intensity quantification, regions of interest 
(ROI) were selected from each image, and the mean gray value (MGV) was quantified 
at each time point. Surface intensity plots were also created from the same-segmented 
Fig. 3 Integrated Balb/c mouse IVM‑RF setup. Panel a Copper tape grounds the mouse to the platform (all 
extremities, including ears, paws, feet, and tail) and secures the nose to the anesthesia tube. (The white scale 
bar represents 1 cm.) Sutures position the skin flap, so that the tumor has preferential orientation in the RF 
field. The region of the incision (but not the tumor) has been blurred out for instructional purposes, so that 
the location of the tumor is in clear view. A dotted line shows the approximate incision line, and the arrow 
indicates the tumor. Panel b Water‑immersion lens is positioned over coverslip that is positioned over the 
surgically exposed tumor. Panel c RX and TX RF antennas on either side of platform
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region to show the perfusion over time. For percent area fraction analysis, images were 
converted to binary images and subsequently inverted. The ratio of white pixels and 
black pixels were used to quantify the areas around the vasculature that were occupied 
by NP over time. In either intensity quantification or percent area fraction analysis, no 
thresholding was performed prior to image binarization, and background intensities 
were not subtracted.
The quantification of cell-sized objects in the blood stream involved tracking the X 
and Y co-ordinates over time of the object’s center of mass, as it interacts with the tunica 
intima. These objects were then used to create a vector that gave the total distance trav-
elled by the object over the selected time frame. The speed of the object was then cal-
culated from this information. During all image analysis techniques, frames that were 
out of focus due to mouse respiration or tissue expansion due to RF field hyperthermia 
were bypassed, and the nearest ‘in focus’ frame at the time point being considered was 
selected in its place.
Results and discussion
Accurate and safe RF-IVM integration is shown in Figs. 2 and 3. Figure 3 presents the 
inclusion of the mouse within the transmitting and receiving antennas of the RF-IVM 
system. The IR camera was able to capture surface temperatures of the tumor location as 
well as a region of healthy tissue over the course of RF field exposure.
Panel C of Fig. 4 shows RF heating, which persisted for 5 min 8 s at a constant power 
of 50 W, resulting in a temperature increase in the tumor, while surface body temper-
ature actually decreased slightly resulting in a final temperature differential of 16.9  °C 
between the body and tumor positions probed. These data are representative of charac-
teristic temperature differential and dynamics observed previously in RF hyperthermia 
experiments (data not shown) in which tumor temperature is initially lower than body 
temperature, but rises, while body temperature remains nearly constant. In this experi-
mental setup, these temperature change dynamics are likely due to the positioning of the 
tumor in the skin flap slightly away from the body and towards the center point of the 
planar surface of the TX RF antenna (Panel A of Fig. 3). As shown in Fig. 4, tumor posi-
tion Spot 2 is approximately 2.1 cm in the X-direction from the center point of the TX 
RF antenna surface. Mouse body position Spot 1 is located approximately 3.4 cm cranial 
to Spot 2 (in the Y-direction) at nearly the same X-distance from the TX antenna sur-
face. (Both spots are approximately located at Z = 0 relative to the stated center point.) 
Given the rapid fall off of electric field strength with increasing distance from the central 
region of the planar surface of the TX antenna (Corr et al. 2015), Spot 1 is substantially 
further away from the region of maximum RF electric field intensity than Spot 2, result-
ing in a final temperature gradient of 5.0 °C/cm between these spots.
The temperatures of 45–47  °C reached within this 5–6  min time frame are above 
the range known to induce hyperthermal shock, decreased migration, balling effect, 
decreased Young’s modulus, greater fluidity, decreased adhesion, and decreased prolif-
eration in cancer cells in vitro (Ware et al. 2015). Furthermore, preferential heating of 
the tumor compared with other body regions demonstrates the safe and targeted heating 
capability of RF hyperthermia treatment. The similarity between these and previously 
reported RF hyperthermia temperature dynamics may further lend support that this 
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portable RF-IVM integrated setup is representative of other larger scale and clinically 
relevant treatment configurations.
Prior to and during the exposure of the mouse tumor to the RF electric field, the intra-
tumoral kinetics and biodistribution of fluorescently-labeled vascular tracer and NPs (as 
mock potential drug carrier) were monitored in the live mouse with confocal microscopy 
(Figs. 5 and 6). Figure 5 shows the dynamics of vascular tracer (Alexafluor-647 conjugated 
BSA) delivery and perfusion through microvasculature in the gland prior to the initia-
tion of RF power dosing, indicative of rapid intravenous perfusion. After the injection of 
Fig. 4 Temperature measurement during the course of IVM imaging under RF field exposure. a, b Photo‑
graphs of mouse and RF‑IVM setup (top) and IR‑camera image (bottom) at time points 0 and 380 s, and c 
tumor surface temperature and body surface temperature measured from IR camera over the course of RF 
field exposure. XYZ co‑ordinates are displayed near the TX RF antenna, where origin (0,0,0) is located at the 
center point of the planar surface of the TX RF antenna
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Fig. 5 Alexafluor‑647 BSA vasculature tracer dynamics. a Fluorescent images during the course of Alex‑
afluor‑647 BSA injection. b Mean gray value (MGV) quantification of the Alexafluo‑647 BSA injection (0 s cor‑
responds to the time when Alexafluor‑647 BSA was administered via tail vein cannulation). The signal remains 
stable for at least 800 s after administration
Fig. 6 Alexafluor‑647 BSA and QD dynamics in tumor vasculature during RF exposure. a Merged images of 
Alexafluor‑647 BSA and QD, b images of QD alone, and c images of Alexafluor‑647 BSA alone, from 18 s to 
5 min 26 s of RF field exposure. RF field exposure induced a temperature increase from 29.6 to 47.1 °C (here, 
shown to 45.2 °C). All images in this figure have been brightened uniformly by changing the original pixel 
saturation level of 4095 to 2465, reducing the dynamic range of pixel intensities to 60 % of the original range
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reagents, Fig. 6 shows the dynamics of both the QDs (Panel B) and the vascular tracer 
(Panel C) before (frame 1) and during (frames 2–5) exposure to a constant 50 W gener-
ated RF field. The frames shown correspond to the time points of temperatures collected 
by the IR camera in Fig. 4. Of note, as the temperature of the tumor region approaches 
45 °C, a morphologically irregular blood vessel in the upper right part of the video image 
in Additional file 3: video with Figure 6 (and video in Supplementary Information) appears 
to swell and burst at ~45  °C, releasing (and/or spreading) both QD and vascular tracer 
into the tumor microenvironment (Fig. 6, Panels B and C, respectively). Regular-shaped 
blood vessels adjacent to this region exhibit far less response to the temperature increase. 
Fluorescence intensity analysis of reagents presented in Figs. 7 and 9 shows that perfusion 
Fig. 7 Surface intensity plots of Alexafluor‑647 BSA perfusion during RF exposure. a Images displaying the 
region of interests at (left) start of RF field exposure and (right) at 310 s time point of RF field exposure. b 
Surface intensity plots which display the perfusion over time and space of Alexaflou‑647 BSA during RF field 
exposure
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of both Alexafluor-647 BSA and QDs in the selected region increased substantially with 
RF hyperthermia. In addition, a detailed and quantitative comparison (percentage area 
fraction of fluorescence of reagents) between regular- and irregular-shaped vasculature is 
provided in Figs. 8 and 10. These data show an increase in perfusion, release, and spread-
ing of reagents during RF exposure only in irregular vessels.
Due to the ease of manipulation of the tumor in the skin flap for positioning directly 
below the objective lens, it is advantageous to use orthotopic breast cancer tumors as a 
cancer model in IVM studies. Furthermore, to ensure heating of the tumor whilst sim-
plifying the analysis, the tumor was positioned, so that it could be directly exposed to 
the strongest part of the RF field without interference from other tissues. With the ini-
tial understanding of dynamic tissue response to RF hyperthermia gained through this 
study, in future IVM studies, we can proceed to the investigation of deeper-seated cancer 
types, such as liver and pancreatic cancers, where the electrical properties of intervening 
Fig. 8 Percentage area fraction analysis of Alexafluor‑647 BSA perfusion during RF exposure in irregular 
tumor vessel versus regular-shaped vessel. a Binary images showing regions of interest in regular looking vas‑
culature, b irregular looking vasculature over the course of RF field exposure, and c time‑resolved quantifica‑
tion of  % area fraction during RF exposure in regular and irregular tumor vascular
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tissues may need to be taken into account. In such cases, we can investigate the tuning of 
parameters that have an effect on the penetration depth of RF radiation, including spe-
cific RF frequency, emission of RF radiation simultaneously from multiple source loca-
tions or via phased emission, and the angle or angles of radiation emission.
The limitation of confocal microscopy in which a pinhole diameter greater than zero 
allows light to “leak” into the image from planes adjacent to the confocal imaging plane, 
makes it necessary to consider some small amount of fluorescence from these planes. 
Based on the optical parameters and microscope specifications of the video images in 
Additional file 2: video with Fig. 5 and Additional file 3: video with Fig. 6, the thickness 
of the confocal planar optical section is estimated at about 0.62 and 0.68 μm for TRITC 
and Cy5 channels, respectively, when accounting for pinhole size (Pawley 2006; Bor-
linghaus 2011). See Additional file 4: Figure S3 for the equation used to calculate these 
thicknesses. Additional file 5: Table S1 describes other experimental pitfalls and trouble-
shooting solutions not considered in the main text.
Fig. 9 Surface intensity plots of QD perfusion during RF exposure. a Images displaying the region of interests 
at (left) start of RF field exposure and (right) at 310 s time point of RF field exposure. b Surface intensity plots 
which display the perfusion over time and space of Alexafluor‑647 BSA during RF field exposure
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Furthermore, for curvature, unevenness and non-level tumor surfaces, the optical sec-
tion will only capture a limited amount of fluorescence from the tumor. Tumor material 
extending too far above the imaging plane toward the objective lens will prevent imaging 
in that region, while a tumor surface that falls away from the imaging plane will not be 
captured either (Pulaski 2001). In our use of the microscope to view specimens, we have 
consistently observed tissue penetration depths ranging from 50 to 100 μm. As a result, 
highly skewed or curved surfaces appear only as a band in the imaging plane with dark 
areas on either side of this band outside of the imaging region.
In the data presented in Figs. 5, 6, 7, 8, 9 and 10, both adjacent plane light and skewed 
or curved tumor surface appear to be only minor issues. The presence of a coverslip 
between the objective lens and the tumor surface may be sufficiently flattening the sur-
face to be in line with the optical section. However, focal plane movement due to breath-
ing artifact and RF-field-induced thermal expansion of tissue presented a challenge to 
maintaining imaging of the same structures through duration of the video and such 
movements may certainly have changed the tumor surface orientation significantly at 
various time points, making the above issues relevant.
Fig. 10 Percentage area fraction analysis of QD perfusion during RF exposure in irregular tumor versus 
regular vessel. a Binary images showing regions of interest in regular looking vasculature, b irregular looking 
vasculature over the course of RF field exposure, and c time‑resolved quantification of  % area fraction during 
RF exposure in regular and irregular looking vascular
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During video image capture, when the image dimmed or went out of focus, efforts 
were made to adjust the focus in real time and based on the reappearance of morpho-
logically equivalent images at similar fluorescence intensities, it was assumed that these 
were the same structures in the same relative positions. However, it is understood that 
the optical section of tissue within the focal plane itself likely moved and warped to an 
extent due to the thermal expansion, so that the repositioning could not be exact, nor 
could the fluorescence intensity be exactly the same after refocusing. These issues reflect 
the nature of real time in situ RF imaging.
Corr et  al. recently measured the RF field between the TX and RX finding that the 
field is strongest within about 1 cm of the TX antenna, although not completely uniform 
(Corr et  al. 2015). The RF field may also change with time and with physical changes 
in and movement of the materials within the field (Corr et  al. 2015). These materials 
include platforms needed to position the mouse and tumor. Therefore, there are limita-
tions on the ability to target exact locations and control the strength of RF electric field 
exposure and resultant heating.
Conclusions
We have provided an accurate protocol that describes the safe integration of IVM imag-
ing with a high-powered non-invasive RF field. The technique allowed us to achieve 
detailed observation over time of the effects of the  RF field on kinetics and biodistri-
bution of NP delivery at the microvascular level in live 4T1 tumor-bearing mice. These 
observations allowed insight into the interaction between the RF field, the vasculature 
and a model NP and will be a useful tool in determining the most efficient RF field treat-
ment schedule for the enhancement of cancer drugs and NP carrier tumor localization. 
Furthermore, the setup and some of the techniques used within this study can be used 
for a wide range of other studies. For instance, we have been able to count and track 
unstained cell-sized objects in the bloodstream (Additional file 6: Figure S2), and thus, 
these techniques can pave the way for the analysis of immune cells, such as macrophage 
interaction in the bloodstream over time. The movement of fluorescent drugs, NPs, or 
cells bearing NPs can be tracked and measured quantitatively with this protocol.
Additional files
Additional file 1: Figure S1.  Absorbance and emission spectra for A) Alexafluor‑647 BSA and B) QD.
Additional file 2: video withFigure 5.  Alexafluor‑647 BSA vasculature tracer dynamics. Fluorescent video during 
the course of Alexafluor‑647 BSA injection.
Additional file 3: video withFigure 6.  Alexafluor‑647 BSA and QD dynamics in tumor vasculature during RF 
exposure.
Additional file 4: Figure S3.  A) Equation for the distance, zmin from the center of the 3D diffraction pattern of a 
point source formed near the focal plane to the first axial minimum of the image, used to define axial resolution of 
the confocal microscope Pawley 2006. B) Equation for optical section thickness, dz as a function of pinhole diameter 
(PH) Borlinghaus 2011. Equation B reduces to Equation A for an ideal pinhole diameter of 0.0 μm but is off by about a 
factor of 2, accounted for in the second term of Equation B. λ0 is the wavelength of light in a vacuum (given for non‑
fluorescence imaging); λexc is the excitation wavelength in fluorescence imaging, n is refractive index of the medium 
between the objective lens and the imaging plane; NA is the numerical aperture of the objective lens.
Additional file 5: Table S1.  Troubleshooting common problems during RF‑IVM experimental procedures.
Additional file 6: Figure S2.  Analysis of dynamics of biological objects in blood stream. A) Images of a large 
vessel and cell‑sized objects (~20μm) interacting with the tunica intima, possibly macrophages. This will allow the 
accurate tracking of blood borne objects in real time during RF field exposure. B) Pixels to micron calibration. C) XY 
co‑ordinate displacement over time and quantification of average speed.
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